UNITED STATES
 SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

 

FORM 8-K

 

CURRENT REPORT
Pursuant To Section 13 or 15(d) Of the Securities And Exchange Act Of 1934

 

February 10, 2004
Date of Report (Date of earliest event reported)

 

WATSON PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

 

Nevada

 

0-20045

 

95-3872914

(State or other Jurisdiction
of Incorporation)

 

(Commission File Number)

 

(IRS Employer
Identification Number)

 

 

 

 

 

311 Bonnie Circle
Corona, California

 

 

 

92880

(Address of principal executive
offices)

 

 

 

(Zip Code)

 

(909) 493-5300
(Registrant’s telephone number, including area code)

 

N/A
(Former Name or Former Address, if Changed Since Last Report)

 

 

 

Item 5.   Other Events.

 

On February 5, 2004, Watson Pharmaceuticals, Inc. (“Watson” or the “Company”), commenced a cash tender offer and consent solicitation for all of its $150,000,000 principal amount of 7 1/8 % Senior Notes due 2008.

 

The Company includes as an exhibit to this Form 8-K the News Release titled “Watson Pharmaceuticals Announces Tender Offer to Repurchase Its 7 1/8% Senior Notes.”

 

Item 7.   Financial Statements, Pro Forma Financial Information and Exhibits.

 

c.               Exhibits

 

99.1                            News Release dated February 5, 2004 titled “Watson Pharmaceuticals Announces Tender Offer to Repurchase Its 7 1/8% Senior Notes.”

 

1

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated:

February 10, 2004.

WATSON PHARMACEUTICALS, INC.

 

 

 

 

By:

  /s/ CHARLES P. SLACIK

 

 

 

Charles P. Slacik

 

 

Executive Vice President and

 

 

Chief Financial Officer

 

2